Animal models of pulmonary hypertension due to left heart disease

被引:9
作者
Liu, Shao-Fei [1 ,2 ,3 ,4 ]
Yan, Yi [5 ,6 ]
机构
[1] Charite Univ Med Berlin, Berlin, Germany
[2] Humboldt Univ, Freie Univ Berlin, Berlin, Germany
[3] Berlin Inst Hlth, Berlin, Germany
[4] DZHK German Ctr Cardiovasc Res, Partner Site Berlin, Berlin, Germany
[5] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Prevent IPEK, Munich, Germany
[6] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, Munich, Germany
关键词
animal model; left ventricular failure; metabolic syndrome; pulmonary hypertension due to left heart disease; pulmonary vascular remodeling; ANGIOTENSIN-CONVERTING ENZYME; PHOSPHODIESTERASE; 5; INHIBITOR; LEFT-VENTRICULAR DYSFUNCTION; RAT MODEL; PROGNOSTIC IMPLICATIONS; ARTERIAL-HYPERTENSION; MYOCARDIAL-INFARCTION; METABOLIC SYNDROME; PRESSURE-GRADIENT; NITRIC-OXIDE;
D O I
10.1002/ame2.12214
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Pulmonary hypertension due to left heart disease (PH-LHD) is regarded as the most prevalent form of pulmonary hypertension (PH). Indeed, PH is an independent risk factor and predicts adverse prognosis for patients with left heart disease (LHD). Clinically, there are no drugs or treatments that directly address PH-LHD, and treatment of LHD alone will not also ameliorate PH. To target the underlying physiopathological alterations of PH-LHD and to develop novel therapeutic approaches for this population, animal models that simulate the pathophysiology of PH-LHD are required. There are several available models for PH-LHD that have been successfully employed in rodents or large animals by artificially provoking an elevated pressure load on the left heart, which by transduction elicits an escalated pressure in pulmonary artery. In addition, metabolic derangement combined with aortic banding or vascular endothelial growth factor receptor antagonist is also currently applied to reproduce the phenotype of PH-LHD. As of today, none of the animal models exactly recapitulates the condition of patients with PH-LHD. Nevertheless, the selection of an appropriate animal model is essential in basic and translational studies of PH-LHD. Therefore, this review will summarize the characteristics of each PH-LHD animal model and discuss the advantages and limitations of the different models.
引用
收藏
页码:197 / 206
页数:10
相关论文
共 93 条
  • [1] Characterization of right ventricular remodeling and failure in a chronic pulmonary hypertension model
    Aguero, Jaume
    Ishikawa, Kiyotake
    Hadri, Lahouaria
    Santos-Gallego, Carlos
    Fish, Kenneth
    Hammoudi, Nadjib
    Chaanine, Antoine
    Torquato, Samantha
    Naim, Charbel
    Ibanez, Borja
    Pereda, Daniel
    Garcia-Alvarez, Ana
    Fuster, Valentin
    Sengupta, Partho P.
    Leopold, Jane A.
    Hajjar, Roger J.
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2014, 307 (08): : H1204 - H1215
  • [2] Resistance to store depletion-induced endothelial injury in rat lung after chronic heart failure
    Alvarez, DF
    King, JA
    Townsley, MI
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2005, 172 (09) : 1153 - 1160
  • [3] Identification of Pulmonary Hypertension Caused by Left-Sided Heart Disease (World Health Organization Group 2) Based on Cardiac Chamber Volumes Derived From Chest CT Imaging
    Aviram, Galit
    Rozenbaum, Zach
    Ziv-Baran, Tomer
    Berliner, Shlomo
    Topilsky, Yan
    Fleischmann, Dominik
    Sung, Yon K.
    Zamanian, Roham T.
    Guo, Haiwei Henry
    [J]. CHEST, 2017, 152 (04) : 792 - 799
  • [4] The neuronal norepinephrine transporter in experimental heart failure:: Evidence for a posttranscriptional downregulation
    Backs, J
    Haunstetter, A
    Gerber, SH
    Metz, J
    Borst, MM
    Strasser, RH
    Kübler, W
    Haass, M
    [J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2001, 33 (03) : 461 - 472
  • [5] Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial
    Bermejo, Javier
    Yotti, Raquel
    Garcia-Orta, Rocio
    Sanchez-Fernandez, Pedro L.
    Castano, Mario
    Segovia-Cubero, Javier
    Escribano-Subias, Pilar
    Alberto San Roman, Jose
    Borras, Xavier
    Alonso-Gomez, Angel
    Botas, Javier
    Crespo-Leiro, Maria G.
    Velasco, Sonia
    Bayes-Genis, Antoni
    Lopez, Amador
    Munoz-Aguilera, Roberto
    de Teresa, Eduardo
    Gonzalez-Juanatey, Jose R.
    Evangelista, Arturo
    Mombiela, Teresa
    Gonzalez-Mansilla, Ana
    Elizaga, Jaime
    Martin-Moreiras, Javier
    Gonzalez-Santos, Jose M.
    Moreno-Escobar, Eduardo
    Fernandez-Aviles, Francisco
    [J]. EUROPEAN HEART JOURNAL, 2018, 39 (15) : 1255 - 1264
  • [6] Bikou O, 2018, METHODS MOL BIOL, V1816, P367, DOI 10.1007/978-1-4939-8597-5_29
  • [7] Riociguat for Patients With Pulmonary Hypertension Caused by Systolic Left Ventricular Dysfunction A Phase IIb Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Hemodynamic Study
    Bonderman, Diana
    Ghio, Stefano
    Felix, Stephan B.
    Ghofrani, Hossein-Ardeschir
    Michelakis, Evangelos
    Mitrovic, Veselin
    Oudiz, Ronald J.
    Boateng, Francis
    Scalise, Andrea-Viviana
    Roessig, Lothar
    Semigran, Marc J.
    [J]. CIRCULATION, 2013, 128 (05) : 502 - U95
  • [8] BLOCKADE OF THE RENIN-ANGIOTENSIN SYSTEM IN CARDIAC PRESSURE-OVERLOAD HYPERTROPHY IN RATS
    BRUCKSCHLEGEL, G
    HOLMER, SR
    JANDELEIT, K
    GRIMM, D
    MUDERS, F
    KROMER, EP
    RIEGGER, GAJ
    SCHUNKERT, H
    [J]. HYPERTENSION, 1995, 25 (02) : 250 - 259
  • [9] Clinical phenotypes and outcomes of pulmonary hypertension due to left heart disease: Role of the pre-capillary component
    Caravita, Sergio
    Faini, Andrea
    D'Araujo, Sandy Carolino
    Dewachter, Celine
    Chomette, Laura
    Bondue, Antoine
    Naeije, Robert
    Parati, Gianfranco
    Vachiery, Jean-Luc
    [J]. PLOS ONE, 2018, 13 (06):
  • [10] The beneficial effects of angiotensin-converting enzyme II (ACE2) activator in pulmonary hypertension secondary to left ventricular dysfunction
    Chen, I-Chen
    Lin, Jao-Yu
    Liu, Yi-Ching
    Chai, Chee-Yin
    Yeh, Jwu-Lai
    Hsu, Jong-Hau
    Wu, Bin-Nan
    Dai, Zen-Kong
    [J]. INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2020, 17 (16): : 2594 - 2602